Helix BioPharma (TSE:HBP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Helix BioPharma reported a net loss of $9.26 million for fiscal 2024, driven by its continued investment in the development of its LDOS47 platform for cancer therapies. The company is refocusing its resources on combination therapy for Non-Small Cell Lung Carcinoma and plans to close its Edmonton laboratory by the end of October 2024.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.